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The continued geographic expansion of Plasmodium
falciparum resistance to artemisinin derivatives is an
urgent public health concern. The last decade has wit-
nessed dramatic progress in global malaria control and
elimination efforts, in large part because of the scale-up
of vector control interventions and improved access to
effective antimalarials, especially artemisinin-based com-
bination therapies (ACTs). Malaria cases have fallen by
>50% in 43 countries since 2001. Since 2000, malaria
mortality rates have declined by >25% globally, and by
>33% in the WHO African Region. Malaria patients
worldwide are dependent on the efficacy of ACTs. In
2010, more than 180 million ACT treatment courses
were procured for the public sector alone.
Resistance to artemisinins was first confirmed on the
Cambodia-Thailand border in late 2006, and reported in
2008. The first containment project - the Artemisinin
Resistance Containment and Elimination (ARCE) project
-was funded by BMGF and coordinated by WHO-GMP;
it ran from late2008-2011. The project did not eliminate
malaria from the affected area; however, active case
detection, strengthened community case management
and better vector control did result in a sustained and
dramatic reduction in Plasmodium falciparum burden.
To mobilize global and local stakeholders for contain-
ment and ultimately elimination of artemisinin resis-
tance, WHO, together with RBM, launched the Global
Plan for Artemisinin Resistance Containment (GPARC) in
January 2011. The GPARC defines priorities to contain
or eliminate artemisinin resistance where it already exists,
or to prevent it where it has not yet appeared. While
strong country-level activities are the central building
blocks in the response, artemisinin resistance does not
respect national boundaries. Resistance has generally
been identified in areas with high numbers of migrants
and close to national borders. Consequently, national
responses to the threat of resistance are not sufficient;
strong regional coordination is crucial.
Despite the emergence of artemisinin resistance in the
Greater Mekong subregion, ACTs remain the most effec-
tive treatment for uncomplicated falciparum malaria; most
patients with delayed response are cured if the partner
drug remains effective. However, mefloquine resistance is
widespread in Thailand and Cambodia, and piperaquine
resistance may have emerged in Western Cambodia, limit-
ing the number of treatment options for uncomplicated
malaria. In addition to the existing foci, there is growing
evidence of resistance to artemisinin, as defined by delayed
parasite clearance times in south-eastern Myanmar and
southern and central Vietnam. It is not known if these
new foci represent spread or de novo emergence of arte-
misinin resistance.
In response to new data, containment efforts have been
started in western Thailand, south-eastern Myanmar and
Vietnam. These new programmes will draw on the lessons
learned during the containment project in Cambodia and
Thailand. In addition, routine monitoring must be
strengthened for the early detection of artemisinin resis-
tance, ensure that recommended first-line ACTs are effec-
tive, and that timely changes in treatment policies can be
made. Many aspects of artemisinin resistance are still not
well understood. Consequently, there is an urgent need for
further research to refine our knowledge of artemisinin
resistance, including the identification of molecular mar-
kers and better in vitro sensitivity tests. These efforts
require full funding to ensure that artemisinin resistance
does not spread and compromise global success in malaria
control and elimination.
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